Controlled release vaccines and methods of treating Brucella diseases and disorders
AssigneeThe Texas A&M University System
InventorsThomas A. Ficht, Allison Ficht, Renee Tsolis, Leslie Garry Adams, Angela M. Arenas-Gamboa
Life of this patent
Estimating the term…
Abstract
Methods and compositions for the treatment of Brucella induced diseases and disorders are disclosed herein. In preferred embodiments, the invention relates to vaccines. In additional embodiments, the invention relates to formulations capable of releasing said vaccines at a controlled rate of release in vivo. In further embodiments, the invention relates to modified strains of the bacteria Brucella melitensis and Brucella abortus. In still further embodiments, the invention relates to compositions that do not induce clinical symptoms or splenomegaly in a subject receiving said compositions.
Claims19
A method for prophylaxis, immunization, amelioration of symptoms, or any combinations thereof against brucellosis in a human or animal subject comprising the steps of:
- identifying the human or animal subject in need of the prophylaxis, immunization, amelioration of symptoms, or any combinations thereof against brucellosis;
- and
- administering a therapeutically effective amount of a vaccine composition to the human or animal subject for the prophylaxis, amelioration of symptoms, or any combinations thereof against brucellosis, wherein the vaccine comprises:
- a double mutant Brucella strain comprising one or more attenuating gene knockouts and a diagnostic gene knockout that is not the attenuating gene knockout, wherein the vaccine composition is free of side effects;
- an encapsulating agent comprising vitelline protein B capable of releasing the Brucella strain at a predetermined rate;
- and
- an adjuvant or a pharmaceutically acceptable carrier.
A vaccine composition that is free of side effects comprising:
- a double mutant Brucella strain comprising one or more attenuating gene knockouts and further comprising a diagnostic gene knockout that is not the attenuating gene knockout, wherein the attenuating gene knockouts comprise ΔmucR, ΔvjbR, ΔvirB2, ΔmanB/A, ΔvirB2/ΔmanB/A mutant, ΔvjbR/ΔmucR mutant, ΔvirB2/ΔmucR mutant, ΔvirB2/ΔvjbR mutant, ΔvjbR/ΔmanB/A mutant, ΔmucR/ΔmanB/A mutant, or any combinations thereof;
- and
- an encapsulating agent comprising vitelline protein B capable of releasing the Brucella strain at a predetermined rate, wherein the vaccine is free of side-effects.
A method of making a vaccine that is free of side effects against brucellosis in an animal subject comprising the steps of:
- providing a double mutant strain of Brucella comprising one or more attenuating gene knockouts and a diagnostic gene knockout that is not the attenuating gene knockout, wherein the attenuating gene knockouts comprise ΔmucR, ΔvjbR, ΔvirB2, ΔmanB/A, ΔvirB2/ΔmanB/A mutant, ΔvjbR/ΔmucR mutant, ΔvirB2/ΔmucR mutant, ΔvirB2/ΔvjbR mutant, ΔvjbR/ΔmanB/A mutant, ΔmucR/ΔmanB/A mutant, or any combinations thereof;
- and
- an encapsulating agent comprising vitelline protein B capable of releasing the Brucella strain at a predetermined rate, wherein the vaccine is free of side effects.
Dependencies are inferred from the claim text.